OG-L002

Research use only, not for human use.

OG-L002 is a novel selective LSD1 inhibitor with IC50 of 20 nM.

OG-L002 is a novel selective LSD1 inhibitor with IC50 of 20 nM; demonstrates significant potency both in inhibition of HSV IE gene expression and in suppression of viral reactivation from latency in a mouse ganglion explant model; also suppresses the expression of the initial class of hCMV and adenovirus genes in vitro; reduces the induction of TNF-α mRNA in splenocytes from mice.

OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 μM in HeLa cells; IC50: ~3 μM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM).

OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. Animal Model:4-week-old BALB/c female mice Dosage:6, 20, 40 mg/kg Administration:Intraperitoneal; daily; for 7 days Result:Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.

OG L002

Chromatin/Epigenetic

Histone Demethylase

LSD1

Infection

——

1357302-64-7

225.3

C15H15NO

>98% (HPLC)

DMSO: 42 mg/mL (186.4 mM); Ethanol: 16 mg/mL (71 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

OC1=CC(C2=CC=C([C@@H]3[C@@H](N)C3)C=C2)=CC=C1

4'-[(1R,2S)-2-aminocyclopropyl]-[1,1'-biphenyl]-3-ol

(-20℃)

With Ice Pack

≥ 2 years